Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung:

Amgen hat positive Ergebnisse aus einer Phase-3-Klinikstudie für eine neue Behandlung gegen Morbus-Basedow (thyreoidale Dystrophie) bekannt gegeben. Gleichzeitig entwickelt Viridian Therapeutics seine eigene Behandlung für diese Krankheit.

Notes on the Translation:

• “Thyroid eye disease” is translated as "Morbus-Basedow" - this is the most common and medically accurate German term.
• I've also included the English term in parentheses for clarity.
• I’ve kept the language concise and direct, mirroring the original text’s style.

Would you like me to:

• Adjust the translation for a specific audience (e.g., layperson vs. medical professional)?
• Expand on a particular aspect of the summary?

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung:

Amgen reagierte auf den Fehlschlag des Medikaments von Viridian Therapeutics und gab positive Ergebnisse für sein eigenes, fortschrittliches Medikament Tepezza bekannt. Dies deutet darauf hin, dass Amgen von dem Rückschlag profitiert.

Translation Breakdown:

• Amgen: Amgen
• reagierte auf: responded to
• den Fehlschlag: the failed trial/crash
• Medikaments von Viridian Therapeutics: of Viridian Therapeutics' drug
• gab positive Ergebnisse bekannt: announced positive results
• fortschrittliches Medikament: next-generation drug
• Dies deutet darauf hin: This suggests/indicates

Do you want me to elaborate on any specific part of the translation or summary, or perhaps provide alternative phrasing for certain sentences?

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Zusammenfassung

Diese Woche im Biotechnologie-Sektor war von einer signifikanten Welle von Zulassungen, wichtigen klinischen Studienergebnissen und mehreren strategischen Akquisitionen geprägt, hauptsächlich in Nordamerika und Europa. Die vielfältigen therapeutischen Bereiche, die betroffen waren – darunter Psoriasis, Asthma, Krebs und seltene Krankheiten – verdeutlichen die Dynamik der Branche.

Zulassungen & Ablehnungen:

Mehrere wichtige Zulassungen wurden erhalten, was den Fortschritt bei der Behandlung verschiedener Erkrankungen zeigt. ARS Pharmaceuticals erhielt die FDA-Zulassung für ihren Epinephrin-Nasenspray, Neffy, wodurch seine Verwendung auf alle Personen über 33 kg erweitert wurde. Novo Nordisk erhielt die FDA-Zulassung für Awiqli, ein wöchentlich wechselndes Basalinsulin für Typ-2-Diabetes, nachdem eine erfolgreiche Resubmission vorlag. Lupin erhielt eine vorläufige FDA-Zulassung für eine generische Version von Sugammadex-Injektion, einem Medikament zur Umkehrung von neuromuskulärer Blockade. Teva erhielt die FDA-Zulassung für sein Biosimilar von Amgens Prolia und die FDA und EMA akzeptierten Tevas Einreichung für ein Biosimilar von Xolair (Ombrelta). Bayer erhielt die Genehmigung der Europäischen Kommission, die Verwendung seines Herzinsuffizienz-Medikaments, Kerendia, für Patienten mit Ausscheidungsfraktionen von 40 % oder höher zu erweitern. GSK erhielt die Genehmigung in China für Exdensur, eine Erhaltungsbehandlung für schweren eosinophilen Asthma. Schließlich erhielt Biogen die FDA-Zulassung für ein hochdosiertes SPINRAZA-Regimen für spinale Muskelatrophie (SMA) auf der Grundlage positiver klinischer Daten.

Strategische Deals & Akquisitionen:

Über Zulassungen hinaus haben bedeutende Deals die Biotechnologie-Landschaft verändert. Eli Lilly gab die Akquisition von Centessa Pharmaceuticals bekannt, wobei der Zugang zu einem vielversprechenden Pipeline-Programm zur OX2R-Agonisten für Schlaf-Wach-Störungen ermöglicht wurde, für einen Gesamtbetrag von etwa 6,3 Milliarden Dollar. Biogen gab ebenfalls die Übernahme von Apellis Pharmaceuticals bekannt, wobei ihre Position in der Immunologie, der seltenen Erkrankung und der Nierenerkrankung gestärkt wurde. Dieser Deal, der sich auf etwa 5,6 Milliarden Dollar einstellte, umfasste die Rechte an Apellis’ SYFOVRE-Behandlung für IgA-Nierenerkrankung. Aurinia Pharmaceuticals vollendete die Akquisition von Kezar Life Sciences, einem klinisch-stadiums Biotechnologie-Unternehmen, für 6,955 Dollar pro Aktie und ein nicht übertragbares Contingent Value Right (CVR).

Klinische Studienergebnisse:

Positive klinische Studienergebnisse untermauerten viele dieser Zulassungen. Insbesondere unterstützten die Daten aus dem ONWARD Phase 3a-Programm die FDA-Zulassung von Novo Nordisks Awiqli. Bayer’s Erweiterung der Verwendung von Kerendia wurde durch positive FINEARTS-HF-Ergebnisse gestützt. Biogens hochdosiertes SPINRAZA-Regimen zeigte verbesserte Motorergebnisse bei SMA-Patienten. GSK’s Exdensur erhielt die Unterstützung von Phase-III-Daten.

Ausblick:

Diese Entwicklungen deuten auf weiterhin Innovationen und Wettbewerb in der Biotechnologiebranche hin. Die Zulassungen und Akquisitionen dürften zu erweiterten Behandlungsoptionen und verstärkten Forschungsbemühungen über eine Reihe von Krankheiten führen. Die Zeitpläne für die Lilly- und Biogen-Deals sind für Ende 2026 bzw. 2026 festgelegt, was die bedeutende, langfristige Investition widerspiegelt, die in diesen Unternehmen getätigt wird.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.39%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.11%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.78%.  June E-mini S&P futures (ESM26) fell -0.43%, and June E-mini Nasdaq futures (NQM26) fell -0.88%.

Stock indexes gave up an early advance on Monday and settled mixed, with the S&P 500 posting a 7.5-month low and the Nasdaq 100 posting a 7.75-month low.  Concerns that a protracted war in the Middle East will derail economic growth weighed on stocks on Monday, along with a sell-off in chip stocks.  Strength in software stocks kept the Dow Jones Industrial Average in positive territory. Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.

Stock indexes initially moved higher on Monday as a decline in bond yields sparked some short covering.  The 10-year T-note yield fell by -8 bp on Monday to 4.34%, amid fears that the war in the Middle East will lead to a fuel shortage that derails global economic growth, offsetting inflation fears and possibly keeping the Fed from raising interest rates.  T-note yields also moved lower on Monday after Fed Chair Powell said inflation expectations are well anchored and that the FOMC will meet its 2% inflation goal. He added, "It's too soon to know what the economic effects will be" from the Iran war.

The US Mar Dallas Fed manufacturing activity survey fell by -0.4 to -0.2, weaker than expectations of an increase to 2.0.

US and Israeli forces pressed ahead with attacks on Iran on Monday, while the UAE issued multiple alerts and Saudi Arabia and Kuwait reported numerous strikes by Iranian drones and missiles as the war in Iran entered its fifth week.  The Washington Post on Monday said the Pentagon is preparing for weeks of ground operations in Iran, as about 3,500 sailors and Marines have arrived in the Middle East.  President Trump told the Financial Times on Sunday that he wants to "take the oil in Iran" and could seize the export hub of Kharg Island, which would involve US ground troops and mark a major escalation of the conflict.

Crude oil prices (CLK26) rose more than +3% on Monday to a 3-week high.  The closure of the Strait of Hormuz, through which about a fifth of the world’s oil and natural gas flows, has choked off oil and gas flows due to Iran’s attacks on shipping in the waterway and forced Gulf producers to cut output because they can’t export from the region.  Iran is also seeking to control ship transit through the Strait of Hormuz, asking vessels to provide lists of crew and cargo, along with voyage details and bills of lading if they want to travel through the waterway.  Goldman Sachs warns that crude prices could exceed the 2008 record high of close to $150 a barrel if flows through the Strait of Hormuz remain depressed through March.

The International Energy Agency said last Monday that more than 40 energy sites across nine countries in the Middle East have been "severely or very severely" damaged, potentially prolonging disruptions to global supply chains once the war in Iran ends.

The markets are discounting a 3% chance for a +25 bp FOMC rate hike at the April 28-29 policy meeting.

Overseas stock markets settled mixed on Monday.  The Euro Stoxx 50 closed up +0.65%.  China's Shanghai Composite closed up +0.24%.  Japan's Nikkei Stock 225 fell to a 3-month low and closed down -2.79%.

Interest Rates

June 10-year T-notes (ZNM6) on Monday closed up by +21 ticks.  The 10-year T-note yield fell -8.4 bp to 4.344%.  June T-notes rallied on Monday amid speculation that the ongoing war in the Middle East will lead to a fuel shortage that derails global economic growth, offsetting inflation fears and possibly keeping the Fed from raising interest rates.  Also, sliding inflation expectations are supportive of T-notes after the 10-year breakeven inflation rate fell to a 3-week low of 2.295% on Monday.  T-notes added to their gains on Monday when Fed Chair Powell said inflation expectations are well anchored and the FOMC will reach its 2% inflation goals.

European government bond yields moved lower on Monday.  The 10-year German bund yield fell -5.9 bp to 3.035%.  The 10-year UK gilt yield fell -4.0 bp to 4.935%.

The Eurozone Mar economic sentiment index fell -1.6 to a 6-month low of 96.6, weaker than expectations of 96.7.

German Mar CPI (EU harmonized) rose +1.2% m/m and +2.8% y/y, right on expectations, with the +2.8% y/y gain the largest year-on-year increase in two years.

Swaps are discounting a 52% chance of a +25 bp ECB rate hike at its next policy meeting on April 30.

US Stock Movers

The weakness in chipmakers and AI infrastructure stocks weighed on the broader market.  Micron Technology (MU) closed down more than -9% to lead losers in the Nasdaq 100, and Western Digital (WDC) closed down more than -8%.  Also, Marvell Technology (MRVL) and Sandisk (SNDK) closed down more than -7%, and Lam Research (LRCX) closed down more than -5%.  In addition, Seagate Technology Holdings Plc (STX), KLA Corp (KLAC), Applied Materials (AMAT), and Intel (INTC) closed down more than -4%, and ASML Holding NV (ASML), Advanced Micro Devices (AMD), and Microchip Technology (MCHP) closed down more than -3%.

Optical stocks retreated on Monday.  Applied Optoelectronics (AAOI) closed down more than -13%, and Coherent (COHR) closed down more than -9%.  Also, Credo Technology Group Holdings Ltd (CRDO) closed down more than -7%, Lumentum Holdings (LITE) closed down more than -6%, and Corning (GLW) closed down more than -5%.

Software stocks rebounded on Monday following last Friday’s plunge.  ServiceNow (NOW) closed up more than +5% to lead gainers in the S&P 500, and Salesforce (CRM) closed up more than +3% to lead gainers in the Dow Jones Industrials.   Also, Workday (WDAY) and Intuit (INTU) closed up more than +3%, and Atlassian (TEAM), Adobe (ADBE), and Autodesk (ADSK) closed up more than +2%.

Cybersecurity stocks moved higher on Monday, recovering some of last Friday’s slide.  Palo Alto Networks (PANW) closed up more than +4%, and Okta (OKTA) and Zscaler (ZS) closed up more than +3%.  Also, CrowdStrike Holdings (CRWD) closed up more than +2% and Fortinet (FTNT) closed up more than +1%.

Aluminum stocks rallied on Monday following Iran’s attacks on Middle Eastern aluminum facilities.  Alcoa (AA) closed up more than +8%, and Century Aluminum (CENX) closed up more than +7%.

Viridian Therapeutics (VRDN) closed down more than -32% after giving efficacy data from a late-stage trial of its experimental therapy for thyroid eye disease of 36%/45% placebo-adjusted proptosis response, well below expectations of 50%+.

Sysco (SYY) closed down more than -15% to lead losers in the S&P 500 after agreeing to buy Jetro Restaurant Depot LLC for $29.1 billion, including debt.

Boston Scientific (BSX) closed down more than -9% after Raymond James downgraded the stock to outperform from strong buy.

United Therapeutics (UTHR) closed up more than +12% after announcing that its study of Tyvasco to treat idiopathic fibrosis met its primary endpoint, demonstrating superiority over placebo.

Insmed Inc. (INSM) closed up more than +5% to lead gainers in the Nasdaq 100 after Morgan Stanley upgraded the stock to overweight from equal weight with a price target of $212.

TKO Group Holdings (TKO) closed up more than +3% after Citizens Financial Group initiated coverage on the stock with a recommendation of market outperform and a price target of $240.

Biogen (BIIB) closed up more than +2% after the FDA approved a high-dose version of its Spinraza drug for spinal muscular atrophy,

Earnings Reports(3/31/2026)

FactSet Research Systems Inc (FDS), McCormick & Co Inc/MD (MKC), nCino Inc (NCNO), NIKE Inc (NKE), PVH Corp (PVH), RH (RH), TD SYNNEX Corp (SNX). On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

1 Trade to Make Now to Position for a Prolonged Iran WarStocks Set to Open Higher as Bond Yields Fall on Fading Rate-Hike Bets, U.S. Jobs Data and Powell’s Remarks AwaitedIran, Oil Prices and Other Key Things to Watch this WeekSony PS5 Price Hikes: Why Raised Prices Could Signal a Red Flag for the Global Economy

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The S&P 500 Index ($SPX) (SPY) on Monday closed down -0.39%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +0.11%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed down -0.78%.  June E-mini S&P futures (ESM26) fell -0.43%, and June E-mini Nasdaq futures (NQM26) fell -0.88%.

Stock indexes gave up an early advance on Monday and settled mixed, with the S&P 500 posting a 7.5-month low and the Nasdaq 100 posting a 7.75-month low.  Concerns that a protracted war in the Middle East will derail economic growth weighed on stocks on Monday, along with a sell-off in chip stocks.  Strength in software stocks kept the Dow Jones Industrial Average in positive territory.

More News from Barchart

Trump Says Micron Is One of the 'Hottest' Stocks. Does That Make MU a Buy Here? Stocks Set to Open Higher as Bond Yields Fall on Fading Rate-Hike Bets, U.S. Jobs Data and Powell’s Remarks Awaited Micron Stock Cools Off — Is MU Now Too Cheap to Ignore? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now!

Stock indexes initially moved higher on Monday as a decline in bond yields sparked some short covering.  The 10-year T-note yield fell by -8 bp on Monday to 4.34%, amid fears that the war in the Middle East will lead to a fuel shortage that derails global economic growth, offsetting inflation fears and possibly keeping the Fed from raising interest rates.  T-note yields also moved lower on Monday after Fed Chair Powell said inflation expectations are well anchored and that the FOMC will meet its 2% inflation goal. He added, "It's too soon to know what the economic effects will be" from the Iran war.

The US Mar Dallas Fed manufacturing activity survey fell by -0.4 to -0.2, weaker than expectations of an increase to 2.0.

US and Israeli forces pressed ahead with attacks on Iran on Monday, while the UAE issued multiple alerts and Saudi Arabia and Kuwait reported numerous strikes by Iranian drones and missiles as the war in Iran entered its fifth week.  The Washington Post on Monday said the Pentagon is preparing for weeks of ground operations in Iran, as about 3,500 sailors and Marines have arrived in the Middle East.  President Trump told the Financial Times on Sunday that he wants to "take the oil in Iran" and could seize the export hub of Kharg Island, which would involve US ground troops and mark a major escalation of the conflict.

Crude oil prices (CLK26) rose more than +3% on Monday to a 3-week high.  The closure of the Strait of Hormuz, through which about a fifth of the world’s oil and natural gas flows, has choked off oil and gas flows due to Iran’s attacks on shipping in the waterway and forced Gulf producers to cut output because they can’t export from the region.  Iran is also seeking to control ship transit through the Strait of Hormuz, asking vessels to provide lists of crew and cargo, along with voyage details and bills of lading if they want to travel through the waterway.  Goldman Sachs warns that crude prices could exceed the 2008 record high of close to $150 a barrel if flows through the Strait of Hormuz remain depressed through March.

Story Continues

The International Energy Agency said last Monday that more than 40 energy sites across nine countries in the Middle East have been "severely or very severely" damaged, potentially prolonging disruptions to global supply chains once the war in Iran ends.

The markets are discounting a 3% chance for a +25 bp FOMC rate hike at the April 28-29 policy meeting.

Overseas stock markets settled mixed on Monday.  The Euro Stoxx 50 closed up +0.65%.  China's Shanghai Composite closed up +0.24%.  Japan's Nikkei Stock 225 fell to a 3-month low and closed down -2.79%.

Interest Rates

June 10-year T-notes (ZNM6) on Monday closed up by +21 ticks.  The 10-year T-note yield fell -8.4 bp to 4.344%.  June T-notes rallied on Monday amid speculation that the ongoing war in the Middle East will lead to a fuel shortage that derails global economic growth, offsetting inflation fears and possibly keeping the Fed from raising interest rates.  Also, sliding inflation expectations are supportive of T-notes after the 10-year breakeven inflation rate fell to a 3-week low of 2.295% on Monday.  T-notes added to their gains on Monday when Fed Chair Powell said inflation expectations are well anchored and the FOMC will reach its 2% inflation goals.

European government bond yields moved lower on Monday.  The 10-year German bund yield fell -5.9 bp to 3.035%.  The 10-year UK gilt yield fell -4.0 bp to 4.935%.

The Eurozone Mar economic sentiment index fell -1.6 to a 6-month low of 96.6, weaker than expectations of 96.7.

German Mar CPI (EU harmonized) rose +1.2% m/m and +2.8% y/y, right on expectations, with the +2.8% y/y gain the largest year-on-year increase in two years.

Swaps are discounting a 52% chance of a +25 bp ECB rate hike at its next policy meeting on April 30.

US Stock Movers

The weakness in chipmakers and AI infrastructure stocks weighed on the broader market.  Micron Technology (MU) closed down more than -9% to lead losers in the Nasdaq 100, and Western Digital (WDC) closed down more than -8%.  Also, Marvell Technology (MRVL) and Sandisk (SNDK) closed down more than -7%, and Lam Research (LRCX) closed down more than -5%.  In addition, Seagate Technology Holdings Plc (STX), KLA Corp (KLAC), Applied Materials (AMAT), and Intel (INTC) closed down more than -4%, and ASML Holding NV (ASML), Advanced Micro Devices (AMD), and Microchip Technology (MCHP) closed down more than -3%.

Optical stocks retreated on Monday.  Applied Optoelectronics (AAOI) closed down more than -13%, and Coherent (COHR) closed down more than -9%.  Also, Credo Technology Group Holdings Ltd (CRDO) closed down more than -7%, Lumentum Holdings (LITE) closed down more than -6%, and Corning (GLW) closed down more than -5%.

Software stocks rebounded on Monday following last Friday’s plunge.  ServiceNow (NOW) closed up more than +5% to lead gainers in the S&P 500, and Salesforce (CRM) closed up more than +3% to lead gainers in the Dow Jones Industrials.   Also, Workday (WDAY) and Intuit (INTU) closed up more than +3%, and Atlassian (TEAM), Adobe (ADBE), and Autodesk (ADSK) closed up more than +2%.

Cybersecurity stocks moved higher on Monday, recovering some of last Friday’s slide.  Palo Alto Networks (PANW) closed up more than +4%, and Okta (OKTA) and Zscaler (ZS) closed up more than +3%.  Also, CrowdStrike Holdings (CRWD) closed up more than +2% and Fortinet (FTNT) closed up more than +1%.

Aluminum stocks rallied on Monday following Iran’s attacks on Middle Eastern aluminum facilities.  Alcoa (AA) closed up more than +8%, and Century Aluminum (CENX) closed up more than +7%.

Viridian Therapeutics (VRDN) closed down more than -32% after giving efficacy data from a late-stage trial of its experimental therapy for thyroid eye disease of 36%/45% placebo-adjusted proptosis response, well below expectations of 50%+.

Sysco (SYY) closed down more than -15% to lead losers in the S&P 500 after agreeing to buy Jetro Restaurant Depot LLC for $29.1 billion, including debt.

Boston Scientific (BSX) closed down more than -9% after Raymond James downgraded the stock to outperform from strong buy.

United Therapeutics (UTHR) closed up more than +12% after announcing that its study of Tyvasco to treat idiopathic fibrosis met its primary endpoint, demonstrating superiority over placebo.

Insmed Inc. (INSM) closed up more than +5% to lead gainers in the Nasdaq 100 after Morgan Stanley upgraded the stock to overweight from equal weight with a price target of $212.

TKO Group Holdings (TKO) closed up more than +3% after Citizens Financial Group initiated coverage on the stock with a recommendation of market outperform and a price target of $240.

Biogen (BIIB) closed up more than +2% after the FDA approved a high-dose version of its Spinraza drug for spinal muscular atrophy,

Earnings Reports(3/31/2026)

FactSet Research Systems Inc (FDS), McCormick & Co Inc/MD (MKC), nCino Inc (NCNO), NIKE Inc (NKE), PVH Corp (PVH), RH (RH), TD SYNNEX Corp (SNX).

On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The S&P 500 Index ($SPX) (SPY) today is down -0.75%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -0.21%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -1.18%.

Stock indexes turned lower this afternoon as the market digests the first $100+ oil settlement since 2022, a milestone reached as supply-chain risks continue to dominate the energy sector.Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.

Treasury Yields retreated after comments from Federal Reserve Chair Jerome Powell noted that while the central bank is tracking the recent surge in energy costs, its tools for addressing such supply-side shocks remain restricted.

The US Mar Dallas Fed manufacturing activity survey fell by -0.4 to -0.2, weaker than expectations of an increase to 2.0.

US and Israeli forces pressed ahead with attacks on Iran today, while the UAE issued multiple alerts and Saudi Arabia and Kuwait reported numerous strikes by Iranian drones and missiles as the war in Iran enters its fifth week.  The Washington Post said the Pentagon is preparing for weeks of ground operations in Iran, as about 3,500 sailors and Marines have arrived in the Middle East. President Trump told the Financial Times on Sunday that he wants to "take the oil in Iran" and could seize the export hub of Kharg Island, which would involve US ground troops and mark a major escalation of the conflict.

Crude oil prices (CLK26) are up more than +2% today at a 3-week high.  The closure of the Strait of Hormuz, through which about a fifth of the world’s oil and natural gas flows, has choked off oil and gas flows due to Iran’s attacks on shipping in the waterway and forced Gulf producers to cut output because they can’t export from the region.  Iran is also seeking to control ship transit through the Strait of Hormuz, asking vessels to provide lists of crew and cargo, along with voyage details and bills of lading if they want to travel through the waterway.  Goldman Sachs warns that crude prices could exceed the 2008 record high of close to $150 a barrel if flows through the Strait of Hormuz remain depressed through March.

The International Energy Agency said last Monday that more than 40 energy sites across nine countries in the Middle East have been "severely or very severely" damaged, potentially prolonging disruptions to global supply chains once the war in Iran ends.

The markets are discounting a 3% chance for a +25 bp FOMC rate hike at the April 28-29 policy meeting.

Overseas stock markets are mixed today.  The Euro Stoxx 50 is up +0.28%.  China's Shanghai Composite closed up +0.24%.  Japan's Nikkei Stock 225 fell to a 3-month low and closed down -2.79%.

Interest Rates

June 10-year T-notes (ZNM6) today are up by +24 ticks.  The 10-year T-note yield is down -9.7 bp to 4.330%.  June T-notes are climbing today on speculation that the ongoing war in the Middle East will lead to a fuel shortage that derails global economic growth, offsetting inflation fears and possibly keeping the Fed from raising interest rates.  Also, sliding inflation expectations are supportive of T-notes after the 10-year breakeven inflation rate fell to a 3-week low of 2.295% today.  T-notes added to their gains today after Fed Chair Powell said inflation expectations are well anchored and the FOMC will reach its 2% inflation goals.

European government bond yields are moving lower today.  The 10-year German bund yield is down -5.5 bp to 3.039%.  The 10-year UK gilt yield is down -4.6 bp to 4.928%.

The Eurozone Mar economic sentiment index fell -1.6 to a 6-month low of 96.6, weaker than expectations of 96.7.

German Mar CPI (EU harmonized) rose +1.2% m/m and +2.8% y/y, right on expectations, with the +2.8% y/y gain the largest year-on-year increase in two years.

Swaps are discounting a 52% chance of a +25 bp ECB rate hike at its next policy meeting on April 30.

US Stock Movers

Software stocks are rebounding today after last Friday’s plunge.  ServiceNow (NOW) is up more than +4%, and Atlassian (TEAM) and Workday (WDAY) are up more than +3%. Also, Datadog (DDOG), Adobe (ADBE), and Autodesk (ADSK) are up more than +2%.  In addition, Intuit (INTU) and Salesforce (CRM) are up more than +1%.

Cybersecurity stocks are rallying today, recovering some of last Friday’s slide.  Palo Alto Networks (PANW) is up more than +6% to lead gainers in the S&P 500.  Also, Okta (OKTA), CrowdStrike Holdings (CRWD), and Zscaler (ZS) are up more than +4%. In addition, Fortinet (FTNT) is up more than +2%.

Aluminum stocks are climbing today following Iran’s attacks on Middle Eastern aluminum facilities.  Alcoa (AA) is up more than +11%, and Century Aluminum (CENX) is up more than +9%.  Also, Kaiser Aluminum (KALU) and Constellium SE (CSTM) are up more than +3%.

Weakness in chipmakers and AI infrastructure stocks is limiting gains in the broader market.  Western Digital (WDC) is down more than -5% to lead losers in the Nasdaq 100, and Marvell Technology (MRVL) and Seagate Technology Holdings Plc (STX) are down more than -5%.  Also, Micron Technology (MU), Lam Research (LRCX), and KLA Corp (KLAC) are down more than -4%, and Applied Materials (AMAT) and Intel (INTC) are down more than -3%.  In addition, ASML Holding NV (ASML), ARM Holdings Plc (ARM), Broadcom (AVGO), and Microchip Technology (MCHP) are down more than -2%.

United Therapeutics (UTHR) is up more than +13% after announcing that its study of Tyvasco to treat idiopathic fibrosis met its primary endpoint, demonstrating superiority over placebo.

Insmed Inc. (INSM) is up more than +5% after Morgan Stanley upgraded the stock to overweight from equal weight with a price target of $212.

TKO Group Holdings (TKO) is up more than +4% after Citizens initiated coverage on the stock with a recommendation of market outperform and a price target of $240.

Biogen (BIIB) is up more than +2% after the FDA approved a high-dose version of its Spinraza drug for spinal muscular atrophy,

Expedia Group (EXPE) is up more than +1% after Jeffries upgraded the stock to buy from hold with a price target of $300.

Viridian Therapeutics (VRDN) is down more than -31% after giving efficacy data from a late-stage trial of its experimental therapy for thyroid eye disease of 36%/45% placebo-adjusted proptosis response, well below expectations of 50%+.

Sysco (SYY) is down more than -11% to lead losers in the S&P 500 after agreeing to buy Jetro Restaurant Depot LLC for $29.1 billion, including debt.

Boston Scientific (BSX) is down more than -8% after Raymond James downgraded the stock to outperform from strong buy.

Earnings Reports(3/30/2026)

AirJoule Technologies Corp (AIRJ), AIRO Group Holdings Inc (AIRO), Arrive AI Inc (ARAI), Arrow Financial Corp (AROW), Bicara Therapeutics Inc (BCAX), DiaMedica Therapeutics Inc (DMAC), Fermi Inc (FRMI), HireQuest Inc (HQI), Inmune Bio Inc (INMB), Innventure Inc (INV), Phreesia Inc (PHR), Progress Software Corp (PRGS), Red Cat Holdings Inc (RCAT), Rezolve AI PLC (RZLV), Riverview Bancorp Inc (RVSB), Tootsie Roll Industries Inc (TR), TuHURA Biosciences Inc (HURA), Zspace Inc (ZSPC). On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Stocks Set to Open Higher as Bond Yields Fall on Fading Rate-Hike Bets, U.S. Jobs Data and Powell’s Remarks AwaitedIran, Oil Prices and Other Key Things to Watch this WeekS&P Futures Slip on Middle East Conflict Uncertainty and China Trade ProbesStocks Plunge Before the Open as Oil Prices Climb on U.S.-Iran Talks Uncertainty

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

The S&P 500 Index ($SPX) (SPY) today is up +0.58%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +0.91%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +0.30%.  June E-mini S&P futures (ESM26) are up +0.38%, and June E-mini Nasdaq futures (NQM26) are up +0.10%.

Stock indexes are climbing today as falling T-note yields sparked short covering.  The 10-year T-note yield is down -10 bp to 4.33% on fears that the war in the Middle East will lead to a fuel shortage that derails global economic growth, offsetting inflation fears and possibly keeping the Fed from raising interest rates.  T-notes yields fell further today after Fed Chair Powell said inflation expectations are well anchored and the FOMC will reach its 2% inflation goals.  He added, "It's too soon to know what the economic effects will be" from the Iran war.Join 200K+ Subscribers: Find out why the midday Barchart Brief newsletter is a must-read for thousands daily.

The US Mar Dallas Fed manufacturing activity survey fell by -0.4 to -0.2, weaker than expectations of an increase to 2.0.

US and Israeli forces pressed ahead with attacks on Iran today, while the UAE issued multiple alerts and Saudi Arabia and Kuwait reported numerous strikes by Iranian drones and missiles as the war in Iran enters its fifth week.  The Washington Post said the Pentagon is preparing for weeks of ground operations in Iran, as about 3,500 sailors and Marines have arrived in the Middle East. President Trump told the Financial Times on Sunday that he wants to "take the oil in Iran" and could seize the export hub of Kharg Island, which would involve US ground troops and mark a major escalation of the conflict.

Crude oil prices (CLK26) are up more than +2% today at a 3-week high.  The closure of the Strait of Hormuz, through which about a fifth of the world’s oil and natural gas flows, has choked off oil and gas flows due to Iran’s attacks on shipping in the waterway and forced Gulf producers to cut output because they can’t export from the region.  Iran is also seeking to control ship transit through the Strait of Hormuz, asking vessels to provide lists of crew and cargo, along with voyage details and bills of lading if they want to travel through the waterway.  Goldman Sachs warns that crude prices could exceed the 2008 record high of close to $150 a barrel if flows through the Strait of Hormuz remain depressed through March.

The International Energy Agency said last Monday that more than 40 energy sites across nine countries in the Middle East have been "severely or very severely" damaged, potentially prolonging disruptions to global supply chains once the war in Iran ends.

The markets are discounting a 3% chance for a +25 bp FOMC rate hike at the April 28-29 policy meeting.

Overseas stock markets are mixed today.  The Euro Stoxx 50 is up +0.28%.  China's Shanghai Composite closed up +0.24%.  Japan's Nikkei Stock 225 fell to a 3-month low and closed down -2.79%.

Interest Rates

June 10-year T-notes (ZNM6) today are up by +24 ticks.  The 10-year T-note yield is down -9.7 bp to 4.330%.  June T-notes are climbing today on speculation that the ongoing war in the Middle East will lead to a fuel shortage that derails global economic growth, offsetting inflation fears and possibly keeping the Fed from raising interest rates.  Also, sliding inflation expectations are supportive of T-notes after the 10-year breakeven inflation rate fell to a 3-week low of 2.295% today.  T-notes added to their gains today after Fed Chair Powell said inflation expectations are well anchored and the FOMC will reach its 2% inflation goals.

European government bond yields are moving lower today.  The 10-year German bund yield is down -5.5 bp to 3.039%.  The 10-year UK gilt yield is down -4.6 bp to 4.928%.

The Eurozone Mar economic sentiment index fell -1.6 to a 6-month low of 96.6, weaker than expectations of 96.7.

German Mar CPI (EU harmonized) rose +1.2% m/m and +2.8% y/y, right on expectations, with the +2.8% y/y gain the largest year-on-year increase in two years.

Swaps are discounting a 52% chance of a +25 bp ECB rate hike at its next policy meeting on April 30.

US Stock Movers

Software stocks are rebounding today after last Friday’s plunge.  ServiceNow (NOW) is up more than +4%, and Atlassian (TEAM) and Workday (WDAY) are up more than +3%. Also, Datadog (DDOG), Adobe (ADBE), and Autodesk (ADSK) are up more than +2%.  In addition, Intuit (INTU) and Salesforce (CRM) are up more than +1%.

Cybersecurity stocks are rallying today, recovering some of last Friday’s slide.  Palo Alto Networks (PANW) is up more than +6% to lead gainers in the S&P 500.  Also, Okta (OKTA), CrowdStrike Holdings (CRWD), and Zscaler (ZS) are up more than +4%. In addition, Fortinet (FTNT) is up more than +2%.

Aluminum stocks are climbing today following Iran’s attacks on Middle Eastern aluminum facilities.  Alcoa (AA) is up more than +11%, and Century Aluminum (CENX) is up more than +9%.  Also, Kaiser Aluminum (KALU) and Constellium SE (CSTM) are up more than +3%.

Weakness in chipmakers and AI infrastructure stocks is limiting gains in the broader market.  Western Digital (WDC) is down more than -5% to lead losers in the Nasdaq 100, and Marvell Technology (MRVL) and Seagate Technology Holdings Plc (STX) are down more than -5%.  Also, Micron Technology (MU), Lam Research (LRCX), and KLA Corp (KLAC) are down more than -4%, and Applied Materials (AMAT) and Intel (INTC) are down more than -3%.  In addition, ASML Holding NV (ASML), ARM Holdings Plc (ARM), Broadcom (AVGO), and Microchip Technology (MCHP) are down more than -2%.

United Therapeutics (UTHR) is up more than +13% after announcing that its study of Tyvasco to treat idiopathic fibrosis met its primary endpoint, demonstrating superiority over placebo.

Insmed Inc. (INSM) is up more than +5% after Morgan Stanley upgraded the stock to overweight from equal weight with a price target of $212.

TKO Group Holdings (TKO) is up more than +4% after Citizens initiated coverage on the stock with a recommendation of market outperform and a price target of $240.

Biogen (BIIB) is up more than +2% after the FDA approved a high-dose version of its Spinraza drug for spinal muscular atrophy,

Expedia Group (EXPE) is up more than +1% after Jeffries upgraded the stock to buy from hold with a price target of $300.

Viridian Therapeutics (VRDN) is down more than -31% after giving efficacy data from a late-stage trial of its experimental therapy for thyroid eye disease of 36%/45% placebo-adjusted proptosis response, well below expectations of 50%+.

Sysco (SYY) is down more than -11% to lead losers in the S&P 500 after agreeing to buy Jetro Restaurant Depot LLC for $29.1 billion, including debt.

Boston Scientific (BSX) is down more than -8% after Raymond James downgraded the stock to outperform from strong buy.

Earnings Reports(3/30/2026)

AirJoule Technologies Corp (AIRJ), AIRO Group Holdings Inc (AIRO), Arrive AI Inc (ARAI), Arrow Financial Corp (AROW), Bicara Therapeutics Inc (BCAX), DiaMedica Therapeutics Inc (DMAC), Fermi Inc (FRMI), HireQuest Inc (HQI), Inmune Bio Inc (INMB), Innventure Inc (INV), Phreesia Inc (PHR), Progress Software Corp (PRGS), Red Cat Holdings Inc (RCAT), Rezolve AI PLC (RZLV), Riverview Bancorp Inc (RVSB), Tootsie Roll Industries Inc (TR), TuHURA Biosciences Inc (HURA), Zspace Inc (ZSPC).

On the date of publication, Rich Asplund did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here’s a 600-word summary of the text, followed by the German translation:

Summary (600 words)

The US stock market is beginning February with gains, driven by indices like the Dow Jones and S&P 500. Investors are closely monitoring economic indicators and geopolitical developments, particularly in the context of fluctuating oil prices and evolving monetary policy, to identify high-growth tech stocks. A key factor is the ability of companies to innovate and adapt to changing economic conditions.

This article from Simply Wall St presents a curated list of 10 US high-growth tech companies, ranked by a “Growth Rating” (★★★☆☆ to ★★★★★☆) based on projected revenue and earnings growth. The list is derived from a stock screener, offering a snapshot of companies with significant potential.

Several companies stand out. Veracyte (VCYT) is a diagnostics company forecasting a substantial 22.4% earnings growth by 2026, leveraging its Afirma GRID platform to advance thyroid cancer diagnostics. monday.com (MNDY) is a global software provider with impressive sales growth (26% revenue forecast), bolstered by strategic partnerships and its AI-driven project management platform. Zeta Global Holdings (ZETA) is a data-driven cloud platform that revised its revenue forecast upwards to $1.73 billion, spurred by the acquisition of Marigold’s enterprise software business and a commitment to R&D.

The listed companies represent diverse sectors within the tech landscape. Marker Therapeutics focuses on innovative therapeutics, Palantir Technologies on data analytics, Workday on enterprise management software, Procore Technologies on construction technology, Cellebrite DI on digital forensics, Sandisk on memory solutions, Zscaler on cybersecurity, Circle Internet Group on digital payments, Viridian Therapeutics on pharmaceutical research, and Duos Technologies Group on data management.

Simply Wall St emphasizes a data-driven, unbiased methodology for its analysis, using historical data and analyst forecasts. The goal is to provide investors with informed insights into potential investments. The article highlights the importance of researching companies’ financial performance, strategic initiatives, and R&D activities. It also points out the significance of monitoring key market indicators and geopolitical events that could impact market dynamics and investor sentiment.

Beyond the top 10, the screener offers a broader selection of 74 US High Growth Tech and AI Stocks, encouraging investors to explore further opportunities, including promising small-cap companies and those trading below their fair value. The article emphasizes utilizing Simply Wall St’s tools, including alerts for critical stock updates, to actively manage a portfolio and stay informed.

The overall message is that identifying high-growth tech stocks requires a combination of careful analysis, a focus on innovation and adaptability, and a keen awareness of the broader economic and geopolitical landscape.

German Translation (600 Wörter)

Zusammenfassung (600 Wörter)

Die US-Aktienmärkte beginnen Februar mit Gewinnen, angetrieben von Indizes wie dem Dow Jones und dem S&P 500. Investoren beobachten die wirtschaftlichen Indikatoren und geopolitischen Entwicklungen genau, insbesondere im Kontext schwankender Ölpreise und sich ändernder Geldpolitik, um vielversprechendes Wachstumspotenzial in der Technologiebranche zu erkennen. Ein entscheidender Faktor ist die Fähigkeit von Unternehmen, innovativ zu sein und sich an veränderte wirtschaftliche Bedingungen anzupassen.

Dieser Artikel von Simply Wall St präsentiert eine kuratierte Liste von 10 US-Technologieunternehmen mit hohem Wachstumspotenzial, geordnet nach einer “Wachstumsbewertung” (★★★☆☆ bis ★★★★★☆) basierend auf prognostizierten Umsatzzahlen und Gewinnwachstum. Die Liste stammt aus einem Aktien-Screening, das einen Momentaufnahme von Unternehmen mit großem Potenzial bietet.

Mehrere Unternehmen stechen hervor. Veracyte (VCYT) ist ein Diagnostikunternehmen, das mit 22,4 % Wachstum in den Gewinnen bis 2026 prognostiziert, und nutzt seine Afirma GRID-Plattform, um die Diagnose von Schilddrücröhrenkrebs voranzutreiben. monday.com (MNDY) ist ein globales Softwareanbieter mit beeindruckendem Umsatzwachstum (26 % Umsatzprognose), gestützt durch strategische Partnerschaften und seine KI-gestützte Projektmanagement-Plattform. Zeta Global Holdings (ZETA) ist eine datengesteuerte Cloud-Plattform, die ihre Umsatzprognose aufgrund der Übernahme von Marigold’s Unternehmenssoftware geschärft hat und sich der Innovation und Forschung verschrieben hat.

Die genannten Unternehmen repräsentieren eine vielfältige Auswahl an Bereichen innerhalb der Technologiebranche. Marker Therapeutics konzentriert sich auf innovative Therapien, Palantir Technologies auf Datenanalysen, Workday auf Enterprise-Management-Software, Procore Technologies auf Bauwesenstechnologie, Cellebrite DI auf digitale Forensik, Sandisk auf Speichersysteme, Zscaler auf Cybersicherheit, Circle Internet Group auf digitale Zahlungen, Viridian Therapeutics auf pharmazeutische Forschung und Duos Technologies Group auf Datenmanagement.

Simply Wall St betont eine datengesteuerte, unvoreingenommene Methodik für seine Analyse, die historische Daten und Analystenprognosen nutzt. Ziel ist es, Investoren mit fundierten Einblicken in potenzielle Investitionen zu versorgen. Der Artikel hebt die Bedeutung der Analyse der finanziellen Leistung, der strategischen Initiativen und der Forschungs- und Entwicklungsaktivitäten von Unternehmen hervor. Er weist auch auf die Bedeutung der Überwachung wichtiger Marktindikatoren und geopolitischer Ereignisse hin, die sich auf Marktdynamik und Anlegerstimmung auswirken können.

Über die Top 10 hinaus bietet das Screening eine breitere Auswahl von 74 US High Growth Tech und KI-Aktien, die Investoren ermutigen, weitere Möglichkeiten zu erkunden, einschließlich vielversprechender Small-Cap-Unternehmen und Unternehmen, die unter ihrem fairen Wert handeln. Der Artikel betont die Verwendung der Tools von Simply Wall St, einschließlich Warnmeldungen für kritische Aktienaktualisierungen, um ein Portfolio aktiv zu verwalten und auf dem Laufenden zu bleiben.

Die Gesamtnachricht ist, dass die Identifizierung von Technologieunternehmen mit hohem Wachstumspotenzial eine Kombination aus sorgfältiger Analyse, einem Fokus auf Innovation und Anpassungsfähigkeit sowie einem ausgeprägten Bewusstsein für die breitere wirtschaftliche und geopolitische Landschaft erfordert.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here’s a 600-word summary of the text, followed by a German translation:

Summary (600 words)

The global market for Thyroid Eye Disease (TED) is experiencing substantial growth, driven by several key factors. Primarily, innovative treatments like monoclonal antibodies targeting the IGF-1 receptor (specifically Teprotumumab, marketed as Tepezza) are offering new hope for patients. Increased awareness of TED, particularly in developed nations, is also fueling demand. However, significant challenges remain, primarily related to cost and access.

TED is an autoimmune condition often linked to hyperthyroidism, resulting in inflammation and swelling that leads to proptosis (bulging eyes), double vision, and discomfort. Previously, treatment options were limited, largely focusing on corticosteroids. The introduction of therapies like Tepezza has revolutionized the field, significantly improving patient outcomes. Ongoing research continues to explore new therapeutic avenues, promising further advancements.

The market is being propelled by several key drivers. Firstly, the approval of Tepezza has created a significant market demand. Secondly, expanding awareness among both patients and healthcare professionals is crucial, leading to earlier diagnoses and improved treatment initiation. Thirdly, the increasing prevalence of thyroid disorders – specifically hyperthyroidism and Graves' disease – is expanding the patient pool requiring treatment.

Despite these positive trends, the market faces obstacles. High treatment costs, particularly for Tepezza, represent a major barrier, especially in emerging economies and for patients lacking comprehensive insurance. Furthermore, limited healthcare infrastructure in regions like Latin America, the Middle East, and parts of Asia restricts access to advanced therapies and proper diagnosis. Treatment side effects, such as those associated with immunosuppressants, also present a challenge.

Key players in the market include Amgen Inc. (developer of Tepezza), Viridian Therapeutics, Inc. (developing Veligrotug – VRDN-001), Tourmaline Bio (developing TOUR006), Alumis Inc. (ACELYRIN, INC.) (developing Lonigutamab), and Harbour BioMed (developing Batoclimab). Several other companies are involved in research and development, including Acelyrin. Viridian Therapeutics' Veligrotug is currently in Phase 3 trials, showing promise in proptosis reduction and double vision resolution. Alumis Inc.'s Lonigutamab is also in Phase 3, with early data demonstrating positive impacts.

The report highlights the value of this information for organizations seeking to navigate this evolving market. It emphasizes the importance of understanding current trends, identifying unmet needs, and developing innovative product strategies. Companies can leverage the report's competitive analysis to refine their strategies, evaluate potential partnerships and acquisitions, and ultimately gain a stronger position in this growing sector.

The market is expected to continue growing at a significant rate over the next decade (2025-2035), driven by ongoing research, technological advancements, and increasing patient awareness. However, addressing the challenges of cost accessibility and infrastructural limitations will be critical for realizing the full market potential.

German Translation (approx. 600 words)

Zusammenfassung des Marktes für Erkrankungen der Schilddrüsen-Augen (TED)

Der globale Markt für Erkrankungen der Schilddrüsen-Augen (TED) verzeichnet ein deutliches Wachstum, das durch mehrere Schlüsselfaktoren angetrieben wird. Vor allem bieten innovative Behandlungen wie Monoklonale Antikörper, die auf den IGF-1-Rezeptor abzielen (insbesondere Teprotumumab, das als Tepezza vermarktet wird), neuen Hoffnung für Patienten. Auch die zunehmende Sensibilisierung für TED, insbesondere in entwickelten Ländern, treibt die Nachfrage an. Es bestehen jedoch erhebliche Herausforderungen, hauptsächlich im Zusammenhang mit Kosten und Zugang.

TED ist eine Autoimmunerkrankung, die oft mit Hyperthyreose (Überfunktion der Schilddrüse) in Verbindung steht und zu Entzündungen und Schwellungen führt, die Proptosis (Einziehungen der Augen), Doppelbilder und Beschwerden verursachen. Bisher waren die Behandlungsoptionen begrenzt und konzentrierten sich hauptsächlich auf Kortikosteroide. Die Einführung von Therapien wie Tepezza hat den Bereich revolutioniert und die Patientenergebnisse deutlich verbessert. Die Forschung geht weiter, um neue therapeutische Wege zu erkunden, was weitere Fortschritte verspricht.

Der Markt wird von mehreren wichtigen Faktoren angetrieben. Erstens hat die Zulassung von Tepezza eine erhebliche Nachfrage erzeugt. Zweitens ist das wachsende Bewusstsein sowohl bei Patienten als auch bei medizinischem Fachpersonal entscheidend und führt zu früheren Diagnosen und verbesserter Behandlungsinitiiierung. Drittens führt die zunehmende Prävalenz von Schilddrüsenerkrankungen – insbesondere Hyperthyreose und Morbus Graves – zu einer größeren Patientenzahl, die eine Behandlung benötigt.

Trotz dieser positiven Trends gibt es Herausforderungen. Die hohen Behandlungskosten, insbesondere für Tepezza, stellen eine erhebliche Hürde dar, insbesondere in Schwellenländern und bei Patienten ohne umfassende Krankenversicherung. Darüber hinaus schränkt die begrenzte Gesundheitsinfrastruktur in Regionen wie Lateinamerika, dem Nahen Osten und Teilen Asiens den Zugang zu fortschrittlichen Therapien und einer korrekten Diagnose ein. Auch Behandlungsnebenwirkungen, wie sie mit Immunsuppressiva verbunden sind, stellen eine Herausforderung dar.

Wichtige Akteure auf dem Markt sind Amgen Inc. (Entwickler von Tepezza), Viridian Therapeutics, Inc. (Entwickler von Veligrotug – VRDN-001), Tourmaline Bio (Entwickler von TOUR006), Alumis Inc. (ACELYRIN, INC.) (Entwickler von Lonigutamab) und Harbour BioMed (Entwickler von Batoclimab). Es gibt mehrere andere Unternehmen, die an Forschung und Entwicklung beteiligt sind, darunter Acelyrin. Viridian Therapeutics' Veligrotug befindet sich derzeit in Phase 3 der klinischen Prüfung und zeigt vielversprechende Ergebnisse bei der Reduzierung von Proptosis und der Auflösung von Doppelbildern. Alumis Inc.'s Lonigutamab befindet sich ebenfalls in Phase 3 und weist anhand früherer Daten positive Auswirkungen auf.

Der Bericht hebt die Bedeutung dieser Informationen für Organisationen hervor, die diesen sich entwickelnden Markt erkunden möchten. Er betont die Bedeutung des Verständnisses aktueller Trends, der Identifizierung ungedeckter Bedürfnisse und der Entwicklung strategischer Produktansätze. Unternehmen können die Erkenntnisse aus dem Bericht nutzen, um ihre Strategien zu verfeinern, potenzielle Partnerschaften und Akquisitionen zu bewerten und sich so eine stärkere Position in diesem wachsenden Sektor zu sichern.

Es wird erwartet, dass der Markt aufgrund laufender Forschung, technologischer Fortschritte und zunehmenden Patientenbewusstseins auch in den nächsten zehn Jahren (2025-2035) weiter wachsen wird. Es ist jedoch entscheidend, die Herausforderungen im Zusammenhang mit den Kosten und den Infrastrukturbeschränkungen zu bewältigen, um das volle Marktpotenzial zu erschließen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Okay, here’s a summary of the text, followed by the German translation:

Summary (600 words max)

The U.S. stock market is currently experiencing volatility, marked by consecutive weekly losses for major indices like the S&P 500 and Dow Jones. Amidst this uncertainty, investors are increasingly turning to high-growth technology (growth tech) stocks, seeking potential for rapid expansion and resilience driven by innovation. These stocks are particularly appealing when broader market concerns are elevated.

The text highlights a list of 10 leading US high-growth tech companies, presented with a “Growth Rating” from Simply Wall St, a financial analysis platform. This rating is based on projected revenue and earnings growth. The list includes companies like Palantir Technologies, Workday, Atlassian, RenovoRx, Procore Technologies, Zscaler, Circle Internet Group, Viridian Therapeutics, and Duos Technologies Group.

Company Deep Dives:

The article then provides detailed overviews of four specific companies: Viridian Therapeutics, AvePoint, and ServiceNow. These profiles offer a closer examination of their operations, revenue growth, earnings, and strategic initiatives.

• Viridian Therapeutics: This biotech firm is focused on developing treatments for thyroid eye disease (TED). The company’s impressive projected annual revenue growth of 46.2% and acceptance of a key FDA application point to significant potential.

• AvePoint: A cloud-native data management software provider, AvePoint has recently achieved profitability and is expanding its offerings, notably with AI governance solutions (AgentPulse), driven by increasing cybersecurity concerns.

• ServiceNow: This company provides cloud-based digital workflow solutions globally. Their strategic focus on AI agent innovation through revamped programs, alongside strong revenue growth (15.2%) and substantial R&D investment, positions them to capitalize on the expanding demand for workflow automation.

Simply Wall St’s Approach:

Simply Wall St is the source of the data and analysis presented. They utilize a growth rating methodology based on projected revenue and earnings growth rates. They provide detailed health reports and historical performance analysis for each company.

Beyond the Top 10:

The article encourages exploration beyond the top 10 list, suggesting investors look at smaller cap companies with strong growth potential, promising cash flow, and optimistic forecasts. It emphasizes the importance of considering analyst and management outlooks.

Disclaimer: The text clearly states that this information is for general informational purposes only and does not constitute financial advice. It is based on historical data and analyst forecasts and should not be used as the sole basis for investment decisions.

German Translation (approx. 600 words)

Zusammenfassung (max. 600 Wörter)

Der US-Aktienmarkt erlebt derzeit eine Phase der Volatilität, gekennzeichnet durch wiederholte wöchentliche Verluste für wichtige Indizes wie den S&P 500 und den Dow Jones. Inmitten dieser Unsicherheit wenden sich Investoren zunehmend an Technologieaktien mit hohem Wachstumspotenzial (High-Growth-Tech-Aktien), um potenzielles schnelles Wachstum und Widerstandsfähigkeit durch Innovation zu suchen, insbesondere wenn allgemeine Marktbedenken hoch sind.

Der Text beleuchtet eine Liste von 10 führenden US-Unternehmen mit hohem Wachstumspotenzial, die mit einer "Wachstumsbewertung" von Simply Wall St, einer Finanzanalyseplattform, präsentiert werden. Diese Bewertung basiert auf prognostizierten Umsatz- und Gewinnwachstumsraten. Die Liste umfasst Unternehmen wie Palantir Technologies, Workday, Atlassian, RenovoRx, Procore Technologies, Zscaler, Circle Internet Group, Viridian Therapeutics und Duos Technologies Group.

Detaillierte Unternehmensanalysen:

Der Artikel bietet detaillierte Profile von vier spezifischen Unternehmen: Viridian Therapeutics, AvePoint und ServiceNow. Diese Profile bieten eine eingehendere Untersuchung ihrer Geschäftstätigkeit, Umsatzwachstum, Gewinne und strategischen Initiativen.

• Viridian Therapeutics: Dieses Biotechnologieunternehmen konzentriert sich auf die Entwicklung von Behandlungen für die Schilddrüsenaugmentation (TED). Das beeindruckende prognostizierte jährliche Umsatzwachstum von 46,2 % und die Akzeptanz eines wichtigen FDA-Antrags deuten auf ein erhebliches Potenzial hin.

• AvePoint: Ein Anbieter von Cloud-basierten Datenmanagement-Software, AvePoint hat kürzlich Rentabilität erreicht und erweitert seine Angebote, insbesondere durch KI-Governance-Lösungen (AgentPulse), angetrieben durch zunehmende Cybersecurity-Bedenken.

• ServiceNow: Dieses Unternehmen bietet weltweit Cloud-basierte digitale Workflow-Lösungen an. Ihr strategischer Fokus auf KI-Agenten-Innovationen durch überarbeitete Programme, zusammen mit starkem Umsatzwachstum (15,2 %) und erheblichen Forschungs- und Entwicklungsinvestitionen, positioniert sie, um die wachsende Nachfrage nach Workflow-Automatisierung zu nutzen.

Simply Wall St's Ansatz:

Simply Wall St ist die Quelle der Daten und Analysen, die in dem Artikel präsentiert werden. Sie verwenden eine Wachstumsbewertungsmethode, die auf prognostizierten Umsatz- und Gewinnwachstumsraten basiert. Sie bieten detaillierte Gesundheitsberichte und historische Performance-Analysen für jedes Unternehmen.

Jenseits der Top 10:

Der Artikel ermutigt dazu, über die Top 10-Liste hinauszuschauen und kleinere Cap-Unternehmen mit hohem Wachstumspotenzial, vielversprechendem Cashflow und optimistischen Prognosen zu prüfen. Es betont die Bedeutung der Berücksichtigung von Analysten- und Management-Ausblicken.

Haftungsausschluss: Der Text gibt klar an, dass diese Informationen nur zu allgemeinen Informationszwecken bereitgestellt werden und keine Finanzberatung darstellen. Sie basiert auf historischen Daten und Analystenprognosen und sollte nicht als alleinige Grundlage für Anlageentscheidungen verwendet werden.